The Northridge, California-based company had a net loss of $21 million on revenue of $1.5 billion for the six months ended October 24, compared with a net loss of $23 million on revenue of $1.3 billion in the corresponding period a year earlier, according to its filing Friday with the US Securities and Exchange Commission. The filing positions the company to join a busy slate of possible debuts in the first months of 2026.Read More
Medtronic’s Diabetes Management Business MiniMed Files for IPO
